The scientific understanding of Parkinson’s disease (PD) has advanced significantly, placing preclinical and clinical research at a critical juncture. However, persistent challenges related to funding and outdated clinical trial methodologies are impeding the pace of innovation and the development of novel therapies. This assessment comes from a leading expert in the field, highlighting the urgent need for systemic changes to accelerate progress for the millions affected by this neurodegenerative disorder.
David Dexter, head of research at Parkinson’s UK, a prominent non-profit organization dedicated to combating the disease, articulated this view in a recent interview with Pharmaceutical Technology. "We know so much more about what causes Parkinson’s now, so there is a strong stream of therapeutics making their way through the pipeline," Dexter stated, underscoring the scientific momentum. He further elaborated on the improved research tools now available, such as patient-derived induced pluripotent stem cells (iPSCs). These advanced models are proving invaluable for testing and evaluating the clinical efficacy of new therapeutic candidates, thereby refining and guiding the drug development process more effectively.
This progress is particularly welcome news for the estimated 10 million individuals globally living with Parkinson’s disease. The current standard of care primarily focuses on managing symptoms, with levodopa, a dopamine precursor, remaining the cornerstone treatment for over five decades since its initial approval. Despite its efficacy in alleviating motor symptoms, levodopa does not halt or reverse the underlying disease progression. Crucially, there are no disease-modifying therapies (DMTs) currently approved for Parkinson’s, leaving a significant unmet need for treatments that can alter the course of the condition.
While researchers and pharmaceutical companies are making strides in better characterizing Parkinson’s and exploring potential DMTs, Dexter emphasized that several critical barriers must be addressed to sustain and accelerate innovation.
Addressing the Parkinson’s Funding Landscape: A Call for Strategic Investment
As the scientific community gains ground in Parkinson’s drug development, Dexter stressed that the allocation of capital to this area is more critical than ever. "Currently, funding to deliver these therapies through the development pipeline to patients’ hands is lacking – primarily due to previous failures in Parkinson’s programmes across the wider pharma landscape," he explained. The history of clinical trial setbacks has, understandably, led to a more cautious investment climate, creating a gap in funding for promising early-stage research.
To counter these economic challenges, Parkinson’s UK has pioneered the Virtual Biotech scheme. This initiative strategically allocates capital to companies and institutions developing both potential DMTs and symptomatic therapies that the organization identifies as having significant promise. The scheme focuses on supporting therapies in the post-target validation and preclinical stages, as well as clinical-stage therapeutics up to Phase II. "We step in at the seed and Series A investment stages to take these projects on, derisk them and take them further down the drug development pipeline," Dexter elaborated.
Parkinson’s UK’s investment strategy is largely target-agnostic. The organization prioritizes scientific merit and robust validation of the proposed approach, irrespective of the specific biological target. This flexible approach has enabled them to support research programs across the United Kingdom, Australia, Finland, and the United States, fostering a global network of innovation. While historically focused on small molecule drugs, Parkinson’s UK is increasingly recognizing the potential of newer therapeutic modalities, including antisense oligonucleotides (ASOs), antibody therapies, and gene silencing approaches, actively seeking promising projects utilizing these advanced technologies.
Catering Treatment to Patient Needs: Acknowledging Heterogeneity and Unmet Symptoms
Parkinson’s disease, like many neurodegenerative disorders, is characterized by significant heterogeneity among patients. This inherent variability complicates the drug development process, as it suggests the existence of distinct subtypes of Parkinson’s. Consequently, identifying specific patient populations for whom a particular drug might be most effective is a crucial, yet challenging, aspect of research.
Furthermore, a major unmet need in Parkinson’s treatment lies in addressing non-motor symptoms. These can include anxiety, depression, insomnia, and cognitive decline, all of which can profoundly impact a patient’s quality of life and overall health, often to a greater extent than motor symptoms. Current treatment paradigms largely overlook or inadequately address these debilitating aspects of the disease.
Dexter does not anticipate the development of a single "magic bullet" that will completely halt Parkinson’s disease in its tracks. Instead, he foresees a future where a combination of therapies, integrating multiple therapeutic approaches, will offer the greatest benefit to patients. This personalized and multifaceted approach will be essential to effectively manage the complex and varied manifestations of the disease.
The current scientific landscape offers a more optimistic outlook for early intervention. "It’s the right time for Parkinson’s, as we now have tests that can identify, with good predictability, if someone is going to develop Parkinson’s in the next 10 to 15 years," Dexter remarked. This predictive capability opens a crucial window for intervention. "The earlier we can get drugs into the system, the better chance we’ve got in stopping symptomatic Parkinson’s," he concluded, emphasizing the potential of proactive therapeutic strategies.
Biomarkers to Guide the Future of Parkinson’s Research: Moving Beyond Subjective Assessments
The variability inherent in Parkinson’s disease is not confined to population-level differences; it can also manifest significantly on a day-to-day basis within an individual patient. This intra-patient variability poses a substantial challenge for clinical trials, as the results obtained can be heavily influenced by the patient’s fluctuating condition on the day of assessment. "This means that the scales are often not fit for purpose, which can result in large variabilities in the clinical data gathered from studies within the space," Dexter explained.
Currently, regulatory bodies often consider the Unified Parkinson’s Disease Rating Scale (UPDRS) as a gold standard endpoint. However, Dexter points out that the UPDRS was primarily designed to evaluate symptomatic therapies, not disease-modifying treatments. This inherent limitation means that its suitability for assessing the efficacy of novel DMTs is questionable, contributing to the variability and potential ambiguity of clinical trial data.
To overcome these hurdles, Dexter advocates for a paradigm shift in clinical trial design. He suggests moving away from subjective clinical assessments and embracing objective, quantifiable measures. This includes a greater reliance on digital biomarkers, blood-based biomarkers, and imaging-based biomarkers. Such an evolution could also lead to a more efficient and cost-effective trial landscape, transitioning from lengthy and expensive studies to shorter, more focused target engagement studies. These shorter studies can rapidly determine if a drug is successfully reaching the brain and interacting with its intended target in a safe manner, thereby accelerating the go/no-go decisions in drug development.
Parkinson’s UK is actively supporting this transition through a separate, non-drug development grant scheme. This initiative funds the development of crucial tools such as diagnostic tests and digital health technologies that can serve as more reliable and objective biomarkers for Parkinson’s research and clinical trials.
The convergence of increased scientific understanding, improved research tools, and a growing recognition of the need for innovative funding and trial methodologies marks a pivotal moment in the fight against Parkinson’s disease. While challenges remain, the expert consensus suggests that a concerted effort to address these systemic barriers could unlock significant breakthroughs, offering renewed hope to millions affected by this debilitating condition. The potential to intervene earlier and more effectively, guided by robust biomarkers and supported by strategic investment, positions the field for unprecedented progress in the coming years.
Leave a Reply